Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2016 10:22 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting

Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
January 07, 2016 10:24 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Announces $41 Million Series C Financing

Austin, Texas, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of...
October 01, 2015 10:15 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance a Stable, Non-Aqueous Diazepam, Subcutaneous Injection for Treatment of Acute Repetitive Seizures in Patients with Epilepsy

Austin, Texas, Oct. 01, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments, was...
April 14, 2015 14:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease

Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for...
January 07, 2015 14:39 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Completes $17.9M Series B Round and Appoints Phillip Johnson as Chief Financial Officer

Austin, Texas, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a clinical-stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs,...
November 12, 2014 10:57 ET | Source: Xeris Pharmaceuticals, Inc.

FDA and EMA Grant Orphan Designation to Xeris Pharmaceuticals' Soluble Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Patients

Austin, Texas, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"),a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable...
June 05, 2014 11:19 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon for the Treatment of Mild-to-Moderate Hypoglycemia

Austin, Texas, June 5, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable...
April 24, 2014 12:19 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps

Austin, Texas, April 24, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable...
April 16, 2014 10:42 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Receives U.S. Patent for its Novel, Stable Non-Aqueous Glucagon Formulations

Austin, Texas, April 16, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,697,644, "Stable Formulations for Parenteral...
October 17, 2013 12:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation

AUSTIN, Texas, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), a clinical stage, specialty biopharmaceutical company developing novel non-aqueous formulations of injectable...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right